Autologous Chondrocyte Transplantation / Implantation Versus Existing treatments

Chondral defects
Which Hospitals?
Your Participation
Study Documents
Local Coordinators
Rehab Physios




To be eligible for the ACTIVE trial you must meet the patient eligibility criteria as set out in the trial schema.

Please read the Patient Information Leaflet carefully if you are thinking about taking part in ACTIVE. The leaflet includes a plan of your journey through the trial.

ACTIVE is a randomised trial so there is approximately a 50:50 chance of whether you receive autologous chondrocyte implantation (ACI) or a non-ACI alternative treatment. The non-ACI alternative will be agreed in advance between you and your surgeon. Your surgeon will only consider you for the trial if he thinks you may benefit from more than one treatment and it is not clear which is the best treatment for you. Remember that before entering the trial you must be prepared to have whichever treatment you are allocated.

It is important to consider the time taken for rehabilitation which may be several months if you have ACI. Your rehabilitation following surgery is very important and the Physiotherapists will advise you on what to do. You can find downloadable advice leaflets for your type of treatment on the Rehab Physios page.

We appreciate your co-operation which is vital to the success of the trial. The results of the trial will help inform surgeons how best to treat chondral defects in the future. We could not do this important work without you.


In December 2007 we began producing a newsletter for patients. The newsletter will continue at fairly regular intervals so please forward to anything you think will help or interest other people with similar knee problems.

Issue 1 (Christmas 2007)

Issue 2 (July 2008)

Issue 3 (February 2012)

Back to top of page


ACTIVE is being carried out by the Robert Jones & Agnes Hunt Orthopaedic & District Hospital NHS Trust in collaboration with the University of Birmingham Clinical Trials Unit and Health Economics Facility. The trial is funded by the Medical Research Council and administrated by Keele University.